Slovenia Is Our Commitment; Evotec Is A Gamechanger: Sandoz’s Stenico
First Part Of Exclusive Interview With Sandoz’s Global Head For Biosimilars
On the sidelines of Medicines for Europe’s 19th biosimilar conference in Amsterdam, Sandoz global biosimilars chief Peter Stenico spoke to Generics Bulletin about the firm’s preparations and strategy ahead of its proposed spinoff from Novartis later this year.
